Read by QxMD icon Read

psychiatric manifestation in parkinson

Hamidreza Khodadadi, Luis J Azcona, Vajiheh Aghamollaii, Mir Davood Omrani, Masoud Garshasbi, Shaghayegh Taghavi, Abbas Tafakhori, Gholam Ali Shahidi, Javad Jamshidi, Hossein Darvish, Coro Paisán-Ruiz
INTRODUCTION: Atypical parkinsonism is a neurodegenerative disease that includes diverse neurological and psychiatric manifestations. OBJECTIVES: We aimed to identify the disease-cauisng mutations in a consanguineous family featuring intellectual disability and parkinsonism. METHODS: Full phenotypic characterization, followed by genome-wide single-nucleotide polymorphism genotyping and whole-genome sequencing, was carried out in all available family members...
October 18, 2016: Movement Disorders: Official Journal of the Movement Disorder Society
Joong Seok Kim, Dong Woo Ryu, Ju Hee Oh, Yang Hyun Lee, Sung Jin Park, Kipyung Jeon, Jong Yun Lee, Seong Hee Ho, Jungmin So, Jin Hee Im, Kwang Soo Lee
BACKGROUND AND PURPOSE: Recent studies have shown that several nonmotor symptoms differ between Parkinson's disease (PD) and drug-induced parkinsonism (DIP). However, there have been no reports on cardiovascular autonomic function in DIP, and so this study investigated whether cardiovascular autonomic function differs between PD and DIP patients. METHODS: This study consecutively enrolled 20 DIP patients, 99 drug-naïve PD patients, and 25 age-matched healthy controls who underwent head-up tilt-table testing and 24-h ambulatory blood pressure monitoring...
October 7, 2016: Journal of Clinical Neurology
Clare M Eddy, Ellice G Parkinson, Hugh E Rickards
Changes in mental state and behaviour have been acknowledged in Huntington's disease since the original monograph in 1872 provided evidence of disinhibition and impaired social cognition. Behavioural problems can manifest before obvious motor symptoms and are frequently the most disabling part of the illness. Although pharmacological treatments are used routinely for psychiatric difficulties in Huntington's disease, the scientific evidence base for their use is somewhat sparse. Moreover, effective treatments for apathy and cognitive decline do not currently exist...
September 20, 2016: Lancet Psychiatry
Shreesh Raj Sammi, Shalini Trivedi, Srikanta Kumar Rath, Abhishek Nagar, Sudeep Tandon, Alok Kalra, Rakesh Pandey
Cholinergic dysfunction is manifested in a plethora of neurodegenerative and psychiatric disorders such as Alzheimer's, Parkinson's, and Huntington's diseases. The extent of cholinergic affliction is maximum in Alzheimer's disease which is a progressive neurodegenerative disorder involving death of cholinergic neurons. To this date, the therapeutic management of cholinergic dysfunction is limited to provide symptomatic relief through the use of acetylcholinesterase (Ache) inhibitors only. The present study elaborates the potential of thyme oil and its individual components in curtailing cholinergic deficits...
September 6, 2016: Molecular Neurobiology
Jorine F van der Heeden, Johan Marinus, Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, Victor J Geraedts, Jacobus J van Hilten
OBJECTIVE: Differences in disease progression in Parkinson disease (PD) have variously been attributed to 2 motor subtypes: tremor-dominant (TD) and postural instability and gait difficulty (PIGD)-dominant (PG). We evaluated the role of these phenotypic variants in severity and progression of nondopaminergic manifestations of PD and motor complications. METHODS: Linear mixed models were applied to data from the Profiling Parkinson's disease (PROPARK) cohort (n = 396) to evaluate the effect of motor subtype on severity and progression of cognitive impairment (Scales for Outcomes in Parkinson's disease [SCOPA]-Cognition [SCOPA-COG]), depression (Hospital Anxiety and Depression Scale [HADS]), autonomic dysfunction (SCOPA-Autonomic [SCOPA-AUT]), excessive daytime sleepiness, psychotic symptoms (SCOPA-Psychiatric Complications [SCOPA-PC]), and motor complications...
June 14, 2016: Neurology
Hao-Lu Hu, Xiu-Shi Ni, Sarah Duff-Canning, Xiao-Ping Wang
Disorders of copper metabolism are associated with neurological dysfunction including Wilson's disease (WD). WD is a autosomal recessive disorder caused by mutations in the ATP7B gene resulting in the inability of the hepatocytes to remove excess copper. Gradual copper accumulation causes damage to liver, brain and other organs manifesting in liver disease, neurological and psychiatric symptoms. Also scond copper-neurometaboic disorder: Menkes disease charaterized with mutated ATP7A gene, is ralated with abnormally neuroal transmission and synaptogenesis...
2016: American Journal of Translational Research
Pai-Yi Chiu, Chun-Tang Tsai, Ping-Kun Chen, Whe-Jen Chen, Te-Jen Lai
BACKGROUND AND PURPOSE: Previous studies on the clinical and pathological manifestations of Parkinson's disease dementia (PDD) have reported findings more similar to dementia with Lewy bodies (DLB) than to Alzheimer's disease (AD). The aim of this study was to investigate the neuropsychiatric symptoms of PDD compared to DLB and AD. METHODS: We conducted a retrospective case-control study on 125 newly diagnosed consecutive PDD patients and age- and dementia stage-matched controls with either DLB (N = 250) or AD (N = 500) who visited the same hospital over the same period...
2016: PloS One
Osama A Abulseoud, Aimen Kasasbeh, Hoon-Ki Min, Julie A Fields, Susannah J Tye, Stephan Goerss, Emily J Knight, Shirlene M Sampson, Bryan T Klassen, Joseph Y Matsumoto, Cynthia Stoppel, Kendall H Lee, Mark A Frye
BACKGROUND: The clinical and neurobiological underpinnings of transient nonmotor (TNM) psychiatric symptoms during the optimization of stimulation parameters in the course of subthalamic nucleus deep brain stimulation (STN-DBS) remain under intense investigation. METHODS: Forty-nine patients with refractory Parkinson's disease underwent bilateral STN-DBS implants and were enrolled in a 24-week prospective, naturalistic follow-up study. Patients who exhibited TNM psychiatric manifestations during DBS parameter optimization were evaluated for potential associations with clinical outcome measures...
2016: Stereotactic and Functional Neurosurgery
Anna Castrioto, Stéphane Thobois, Sebastien Carnicella, Audrey Maillet, Paul Krack
Neuropsychiatric symptoms are common and disabling in PD. Their neurobiological bases are complex, partly because of the disease itself and partly because of the dopaminergic treatment. The aim of this review is to focus on the emotional manifestations stemming from the neurodegenerative process itself. We focus on depression, anxiety, apathy, and fatigue, which can all be part of the clinical spectrum of premotor disease and may be improved or masked by medications targeting parkinsonian motor signs or psychiatric symptoms as the disease progresses...
August 2016: Movement Disorders: Official Journal of the Movement Disorder Society
Carlos R Plata-Salaman
Cytokines (e.g. various interleukins and subfamily members, tumor necrosis factors, interferons, chemokines and growth factors) act in the brain as immunoregulators and neuromodulators. Over a decade ago, the integrative article 'Immunoregulators in the Nervous System' (Neurosci Biobehav Rev 1991; 15: 185-215) provided a comprehensive framework of pivotal issues on cytokines and the nervous system that recently have been extensively studied. Cytokine profiles in the brain, including cytokine generation and action, have been studied in multiple models associated with neuropathophysiological conditions...
December 2002: Acta Neuropsychiatrica
Estrella Gómez-Tortosa, Cristina Prieto-Jurczynska, Soledad Serrano, Emilio Franco-Macías, Laura Olivié, Jesús Gallego, Rosa Guerrero-López, María José Trujillo-Tiebas, Carmen Ayuso, Pedro García Ruiz, Julián Pérez-Pérez, María José Sainz
For diagnostic purposes, we screened for the C9ORF72 mutation in a) 162 FTLD cases, and b) 145 cases with other diagnoses but with some frontotemporal features or manifestations previously reported in C9 carriers. Ten cases (onset 50 to 75 years) harbored the expansion: seven had FTLD syndromes (4.3% of total, 11% of familial cases), and three (2%) had a different diagnosis. All positive cases had family history of dementia, psychiatric disease, or ALS, but only 20% of families with mixed FTLD/ALS phenotypes carried the expansion...
February 26, 2016: Journal of Alzheimer's Disease: JAD
Michele Ragno, Sandro Sanguigni, Antonio Manca, Luigi Pianese, Cristina Paci, Alfonso Berbellini, Valeria Cozzolino, Roberto Gobbato, Silvio Peluso, Giuseppe De Michele
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common hereditary cerebral small vessel disease, is caused by mutations in the NOTCH3 gene on chromosome 19. Clinical manifestations of CADASIL include recurrent transient ischemic attacks, strokes, cognitive defects, epilepsy, migraine and psychiatric symptoms. Parkinsonian features have variably been reported in CADASIL patients, but only a few patients showed a clear parkinsonian syndrome. We studied two patients, a pair of monozygotic twins, carrying the R1006C mutation of the NOTCH3 gene and affected by a parkinsonian syndrome...
June 2016: Neurological Sciences
Bai-Yun Zeng, Kaicun Zhao
Parkinson's disease is a neurodegenerative disorder. Parkinson's clinical feature is characterized by its motor manifestations, although its many nonmotor symptoms occur earlier and have more profound impact on the quality of patient's life. Acupuncture has been increasingly popular and has been used to treat patients with Parkinson's. In this article, we have studied the clinical reports of acupuncture treatment for Parkinson's, which were listed in Medline, PubMed, EMBASE, CNKI, and CINAHL databases in the past 15 years...
May 2016: CNS Neuroscience & Therapeutics
Carlo Wilke, Jörn K Pomper, Saskia Biskup, Cornelia Puskás, Daniela Berg, Matthis Synofzik
While C9orf72 repeat expansions usually present with frontotemporal dementia (FTD) and/or amyotrophic lateral sclerosis (ALS), an increasing number of reports suggests that the primary phenotype of C9orf72 patients may also include movement disorders. We here provide the first systematic clinical characterisation of C9orf72-associated parkinsonism. We report a C9orf72 expansion carrier presenting with a clinical syndrome of progressive supranuclear palsy (PSP), pronounced mesencephalic atrophy on MRI and PSP-characteristic electrooculography findings...
March 2016: Journal of Neurology
Dawit Kibru Worku, Yared Mamushet Yifru, Douglas G Postels, Fikre Enquselassie Gashe
BACKGROUND: Parkinson's disease (PD) is associated with cognitive and psychiatric disturbances including depression, anxiety, psychotic symptoms and sleep disturbances. These psychiatric manifestations have a negative impact on disease course and the medical management of PD patients. Major depression has a greater negative impact on patients' quality of life than abnormal motor function, and is associated with faster cognitive decline and progression of motor deficits. Thus, the objective of this study was to determine the prevalence and pattern of depression in PD outpatients in Ethiopia...
2014: Journal of Clinical Movement Disorders
Jing Zou, Rui-Hui Weng, Zhao-Yu Chen, Xiao-Bo Wei, Rui Wang, Dan Chen, Ying Xia, Qing Wang
Premotor Parkinson's disease (PD) refers to a prodromal stage of Parkinson's disease (PD) during which nonmotor clinical features may be present. Currently, it is difficult to make an early diagnosis for premotor PD. Molecular imaging with position emission tomography (PET) or single-photon emission tomography (SPECT) offers a wide variety of tools for overcoming this difficulty. Indeed, molecular imaging techniques may play a crucial role in diagnosing, monitoring and evaluating the individuals with the risk for PD...
March 2016: CNS Neuroscience & Therapeutics
Bing Pan, Weibo Liu, Qiaozhen Chen, Leilei Zheng, Yingying Bao, Huichun Li, Risheng Yu
Idiopathic basal ganglia calcification (IBGC) is a rare neurodegenerative disorder characterized by the deposition of calcium in the brain and variable combinations of movement disorders, gait impairment and neuropsychiatric symptoms. Few reports have described psychiatric manifestations as early symptoms of IBGC. The present study reports the case of a middle-aged man with schizophrenia-like psychosis and obsessive-compulsive symptoms as the first manifestations of IBGC. The response of the patient to olanzapine and fluoxetine suggests that low-dose olanzapine is effective and should be increased cautiously to avoid worsening parkinsonism and that fluoxetine is an effective drug for the treatment of obsessive-compulsive symptoms in IBGC...
August 2015: Experimental and Therapeutic Medicine
Sarah-Gabrielle Béland, Ronald B Postuma, Véronique Latreille, Josie-Anne Bertrand, Michel Panisset, Sylvain Chouinard, Christina Wolfson, Jean-François Gagnon
BACKGROUND: Parkinson's disease is characterized by numerous non-motor symptoms, including sleep disorders. Sleep apnea has been reported in a substantial proportion of patients with Parkinson's disease, but it is unclear whether it has significant consequences for the quality of life of those affected or whether it is associated with other manifestations of the disease. OBJECTIVE: To verify whether sleep apnea is associated with more severe motor and non-motor clinical features in Parkinson's disease...
2015: Journal of Parkinson's Disease
Matthieu F Bastide, Wassilios G Meissner, Barbara Picconi, Stefania Fasano, Pierre-Olivier Fernagut, Michael Feyder, Veronica Francardo, Cristina Alcacer, Yunmin Ding, Riccardo Brambilla, Gilberto Fisone, A Jon Stoessl, Mathieu Bourdenx, Michel Engeln, Sylvia Navailles, Philippe De Deurwaerdère, Wai Kin D Ko, Nicola Simola, Micaela Morelli, Laurent Groc, Maria-Cruz Rodriguez, Eugenia V Gurevich, Maryka Quik, Michele Morari, Manuela Mellone, Fabrizio Gardoni, Elisabetta Tronci, Dominique Guehl, François Tison, Alan R Crossman, Un Jung Kang, Kathy Steece-Collier, Susan Fox, Manolo Carta, M Angela Cenci, Erwan Bézard
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years...
September 2015: Progress in Neurobiology
E Oikonomou, Th Paparrigopoulos
Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease affecting 1-2% of the population over 60. Although diagnosed by its characteristic motor manifestations, PD may be preceded, and is frequently accompanied, by a wide range of psychiatric and cognitive symptoms. These symptoms are often more debilitating than its motor complications and it is nowadays appreciated that they can be an important cause of excess disability in PD, frequently necessitating hospitalization and institutionalization...
April 2015: Psychiatrikē, Psychiatriki
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"